Research-based pharmaceutical and healthcare company GlaxoSmithKline (GSK) has received a proposal from Aspen Global and Aspen Pharmacare Holdings for its thrombosis brands and Notre-Dame de Bondeville (NDB) site.
The offer includes the transfer of GSK’s Arixtra and Fraxiparine brands, not including China, India and Pakistan, in addition to associated manufacturing site to Aspen.
Employees at NDB in France and certain commercial employees will also be transferred upon execution of the deal.
GSK has agreed to a period of exclusivity with Aspen and a decision is likely to be reached after consulting with its employees and the relevant works councils.
The proposal is in lines with its strategy of focusing on products with the growth potential and the delivery of its pipeline, according to the company. Financial terms of the transaction have not been disclosed.
